Drug intelligence / Profile preview

DMRA-301

Development stage: Preclinical
Lead developer: Damora Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

DMRA-301 is a preclinical biologic candidate, specifically a monoclonal antibody, being developed by Damora Therapeutics for the treatment of myeloproliferative neoplasms (MPNs), such as essential thrombocythemia and myelofibrosis. The drug is designed to selectively target the mutant form of calreticulin (CALR), which is characterized by a unique C-terminal neoepitope. In CALR-mutant MPNs, this mutant protein binds to and constitutively activates the thrombopoietin receptor (MPL), driving malignant cell proliferation. By binding to mutant CALR, DMRA-301 aims to disrupt the CALR-MPL interaction and eliminate mutant clones. Damora Therapeutics expects to file an Investigational New Drug (IND) application for its CALR-targeting programs in 2026.

Targets

CALR mutant (Calreticulin Mutant Protein)

Beyond the preview

Go deeper on DMRA-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMRA-301.

Explore the full profile